Donepezil Hydrochloride Torrent Pharma (Uk)

Donepezil Hydrochloride Torrent Pharma (UK) is an oral tablet that contains the active ingredient donepezil hydrochloride. Classified as an acetylcholinesterase inhibitor, it is used for the symptomatic treatment of Alzheimer’s disease in adults with mild to moderate cognitive decline. The product is marketed within the European Union and complies with the regulatory standards applicable to central nervous system agents and is supplied by Torrent Pharma under UK licensing.

Donepezil Hydrochloride is indicated for the management of cognitive symptoms associated with Alzheimer’s disease.

- Improves memory and attention in patients with mild to moderate Alzheimer’s disease. - Supports daily functioning by enhancing cholinergic neurotransmission. - Used as part of a comprehensive care plan that includes non‑pharmacologic interventions. - May be considered when other cholinesterase inhibitors are not tolerated. - Prescribed by a qualified healthcare professional after diagnosis confirmation.

Side effects of Donepezil Hydrochloride can vary in frequency and severity; they are typically reported during the first weeks of therapy.

Common: - Nausea or vomiting. - Diarrhea or abdominal discomfort. - Insomnia or vivid dreams. - Muscle cramps or weakness. - Fatigue or decreased energy. - Loss of appetite.

Serious: - Bradycardia or heart block. - Severe allergic reactions such as rash, swelling, or difficulty breathing. - Hepatic dysfunction indicated by jaundice or abnormal liver tests. - Seizures or convulsions. - Persistent dizziness leading to falls.

When prescribing Donepezil Hydrochloride, clinicians should evaluate several precautionary factors to ensure safe use.

- Assess cardiac history, especially bradyarrhythmias or sick sinus syndrome. - Review concurrent use of other cholinergic or anticholinergic agents. - Monitor liver function in patients with hepatic impairment. - Use caution in patients with asthma or chronic obstructive pulmonary disease. - Evaluate renal function, although dose adjustment is rarely required. - Consider pregnancy and breastfeeding status; safety data are limited. - Counsel patients on the potential for gastrointestinal upset and advise taking the medication with food if needed.

Donepezil Hydrochloride may interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid: - Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole). - Co‑administration with anticholinergic drugs that may reduce therapeutic efficacy. - Use with other acetylcholinesterase inhibitors.

Use with caution: - Beta‑blockers or calcium channel blockers due to additive bradycardia risk. - NSAIDs or anticoagulants because of potential gastrointestinal bleeding. - Drugs that affect cardiac conduction such as digoxin.